Publication | Closed Access

Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure

HypertensionHeart FailureCardiovascular DiseaseLong-term EfficacyAntihypertensive TherapyPharmacologyCardiovascular PharmacologyPharmacotherapyCardiac Metaiodobenzylguanidine ActivityCardiovascular ToxicityMedicineCardiologyMyocardial Infarction